VOLITIONRX LTD — Director's Dealing 2020

May 22, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2020-05-22

Reporting Person: Reynolds Cameron John (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-22	Common Stock	P	4000	$2.75	Acquired	1126273	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	34076	Indirect
Common Stock	1007718	Indirect

Footnotes

F1: The shares were purchased by the reporting person in connection with an underwritten public offering by the Issuer. The offering closed on May 22, 2020. The reported sale price reflects the price at which the reporting person purchased the shares from the underwriter.

F2: The shares of Common Stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of Common Stock held by Concord International, Inc.